Laughon B - Search Results

1

Remembering the Host in Tuberculosis Drug Development.

Frank DJ, Horne DJ, Dutta NK, Shaku MT, Madensein R, Hawn TR, Steyn AJC, Karakousis PC, Kana BD, Meintjes G, Laughon B, Tanvir Z. Frank DJ, et al. Among authors: laughon b. J Infect Dis. 2019 Apr 19;219(10):1518-1524. doi: 10.1093/infdis/jiy712. J Infect Dis. 2019. PMID: 30590592 Free PMC article. Review.

2

Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility.

Goldman RC, Laughon BE, Reynolds RC, Secrist JA 3rd, Maddry JA, Guié MA, Poffenberger AC, Kwong CA, Ananthan S. Goldman RC, et al. Among authors: laughon be. Infect Disord Drug Targets. 2007 Jun;7(2):92-104. doi: 10.2174/187152607781001790. Infect Disord Drug Targets. 2007. PMID: 17970221

3

Tuberculosis - drugs in the 2016 development pipeline.

Laughon BE, Nacy CA. Laughon BE, et al. Nat Rev Dis Primers. 2017 Mar 9;3:17015. doi: 10.1038/nrdp.2017.15. Nat Rev Dis Primers. 2017. PMID: 28276432 No abstract available.

4

New tuberculosis drugs in development.

Laughon BE. Laughon BE. Curr Top Med Chem. 2007;7(5):463-73. doi: 10.2174/156802607780059736. Curr Top Med Chem. 2007. PMID: 17346192 Review.

5

The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.

Goldman RC, Plumley KV, Laughon BE. Goldman RC, et al. Among authors: laughon be. Infect Disord Drug Targets. 2007 Jun;7(2):73-91. doi: 10.2174/187152607781001844. Infect Disord Drug Targets. 2007. PMID: 17970220 Review.

6

New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.

Lee SFK, Laughon BE, McHugh TD, Lipman M. Lee SFK, et al. Among authors: laughon be. Curr Opin Pulm Med. 2019 May;25(3):271-280. doi: 10.1097/MCP.0000000000000570. Curr Opin Pulm Med. 2019. PMID: 30865034 Review.

7

From the National Institutes of Health. Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS.

Laughon BE, Allaudeen HS, Becker JM, Current WL, Feinberg J, Frenkel JK, Hafner R, Hughes WT, Laughlin CA, Meyers JD, et al. Laughon BE, et al. J Infect Dis. 1991 Aug;164(2):244-51. doi: 10.1093/infdis/164.2.244. J Infect Dis. 1991. PMID: 1649870 No abstract available.

8

Recovery of Campylobacter species from homosexual men.

Laughon BE, Vernon AA, Druckman DA, Fox R, Quinn TC, Polk BF, Bartlett JG. Laughon BE, et al. J Infect Dis. 1988 Aug;158(2):464-7. doi: 10.1093/infdis/158.2.464. J Infect Dis. 1988. PMID: 3403996 No abstract available.

9

Discovery and validation of new antitubercular compounds as potential drug leads and probes.

Goldman RC, Laughon BE. Goldman RC, et al. Among authors: laughon be. Tuberculosis (Edinb). 2009 Sep;89(5):331-3. doi: 10.1016/j.tube.2009.07.007. Epub 2009 Aug 28. Tuberculosis (Edinb). 2009. PMID: 19716767 Free PMC article.

10

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, Secrist JA 3rd, Shindo N, Showe DN, Sosa MI, Suling WJ, White EL. Ananthan S, et al. Among authors: laughon be. Tuberculosis (Edinb). 2009 Sep;89(5):334-53. doi: 10.1016/j.tube.2009.05.008. Epub 2009 Sep 15. Tuberculosis (Edinb). 2009. PMID: 19758845 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page